Komori
Zeria Pharmaceutical (4559) · RiskMitigated

Credit, market and liquidity risks related to financial instruments

First written in FY2017. 2 of 5 entries say "Mitigated", first in FY2018. Latest entry: FY2024.

5entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017MitigatedFY2018RestatedFY2019 – FY20202017: 120172018: 120182019: 120192020: 120202021: 020212022: 020222023: 020232024: 12024
Same theme, other companies

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024MitigatedAnnual report

    「Our group has entered into overdraft agreements and loan commitment agreements with 6 relationship banks, securing total credit facilities of ¥33.45 billion (unused amount at 31 March 2024: ¥10.22524 billion).」

    The commitment facilities were changed from 7 banks and ¥32.45 billion to 6 banks and ¥33.45 billion, with an unused facility of ¥10.22524 billion secured.
  2. FY2020RestatedAnnual report

    「Our group has entered into overdraft agreements and loan commitment agreements with 7 relationship banks, securing total credit facilities of ¥31.45 billion (unused amount at 31 March 2020: ¥12.546334 billion).」

    The company maintained agreements totaling ¥31.45 billion with 7 banks and secured an unused facility of ¥12.546334 billion.
  3. FY2019RestatedAnnual report

    「Our group has entered into overdraft agreements and loan commitment agreements with 7 relationship banks, securing total credit facilities of ¥31.45 billion (unused amount at 31 March 2019: ¥13.939337 billion).」

    The company maintained agreements totaling ¥31.45 billion with 7 banks, continuing its response to liquidity risk.
  4. FY2018MitigatedAnnual report

    「Our group has entered into overdraft agreements and loan commitment agreements with 8 relationship banks, securing total credit facilities of ¥3.145 billion (unused amount at 31 March 2018: ¥1.7422 billion).」

    The company secured agreements with 8 banks totaling ¥3.145 billion and an unused facility of ¥1.7422 billion, rather than ¥174.2 million, thereby specifying its response to liquidity risk.
  5. FY2017First statedAnnual report

    「Notes and accounts receivable, which are trade receivables, are exposed to customers’ credit risk. Investment securities consist primarily of shares in companies with which we have business relationships and are exposed to the risk of fluctuations in market prices.」

    The company identifies credit risk on trade receivables, price fluctuation risk on investment securities, foreign exchange risk on foreign-currency-denominated liabilities, interest rate risk on borrowings, and liquidity risk at settlement as risks relating to financial instruments.
Moved together

"Further Strengthening of the Financial Position" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Further Strengthening of the Financial Position2×
  3. 2Stable and Consistent Dividends and Strengthening Retained Earnings2×
  4. 3Recovery in Revenue, Operating Profit and Net Income2×
  5. 4Growth of the Prescription Pharmaceutical Business Driven by Asacol, Acofide, and Entocort2×
  6. 5Expansion of the Consumer Healthcare Business Centered on Hepalyse2×
  7. 6Progress in Clinical Trials and Regulatory Filings for Multiple Products2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.